Relay Therapeutics, Inc. RLAY

RLAY Company Overview

Relay Therapeutics, Inc. is a clinical-stage precision medicine company focused on developing targeted therapies for oncology and genetic diseases through the integration of computational chemistry, structural biology, and machine learning. The company operates within the biotechnology and pharmaceutical industries, with a primary emphasis on discovering and developing small-molecule therapies that modulate protein motion and signaling pathways implicated in disease. Relay Therapeutics’ core strategic positioning is centered on its proprietary Dynamo platform, which combines experimental and computational technologies to analyze protein dynamics at scale in order to identify druggable conformations that may not be accessible through conventional drug discovery approaches.

The company was founded in 2015 and is headquartered in Cambridge, Massachusetts. Relay Therapeutics evolved from research originating at academic institutions including Harvard University and other structural biology research centers. Since its inception, the company has focused on precision oncology programs targeting kinase signaling pathways and genetically defined tumors. Its lead development programs have included therapies targeting FGFR2 alterations, PI3Kα mutations, and RAS pathway signaling. Revenue generation has historically come primarily from collaboration agreements, licensing arrangements, and investment financing, as the company remains in the clinical development stage and has not reported sustained commercial product revenue based on publicly available filings.